Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin type A with microneedle in hemifacial spasm
TCTR20220607003Phase 1Completed
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1 trial of botulinum toxin type A in hemifacial spasm (HFS) (2 arms), sponsored by Ratchadaphiseksomphot Endowment Fund. Primary endpoint: Injection pain at 1 day. Started Feb 2021; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
hemifacial spasm (HFS)
Beyond the preview
Go deeper on TCTR20220607003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220607003.